
Splash: A private oncology pharma developing novel cancer therapies targeting CD44 for solid tumors.
Splash Pharmaceuticals, founded as a privately held company, is dedicated to developing novel cancer therapies with a focus on targeting CD44 to treat solid tumors. Their core mission is to provide dramatic and durable responses in oncology and arthritis patients through innovative treatments. Splash's pipeline includes agents with anti-angiogenic, anti-metastatic properties, and synergistic cytotoxicity when combined with other chemotherapy agents. The company is actively seeking partnerships to accelerate its clinical programs.
Notable figures affiliated with Splash Pharmaceuticals include experienced oncology researchers and industry veterans. The company has secured significant investments from venture capital firms specializing in biotech. Key achievements include the development of their lead candidate, SPL-, which has shown promising safety and efficacy in multiple clinical trials involving numerous human subjects. Splash's impact lies in its potential to revolutionize cancer and arthritis treatment by offering more effective and targeted therapies.

Novita Pharmaceuticals
novita-pharm.com

Camino Pharma
caminopharma.com

Palm Therapeutics

SphynKx Therapeutics

BlossomHill Therapeutics
bhtherapeutics.com

OncoTartis

Window Therapeutics
windowtx.com

OncoSpherix
oncospherix.com

Tango Therapeutics
tangotx.com

OnCusp Therapeutics
oncusptx.com

Checkpoint Therapeutics
checkpointtx.com

Tigris Pharmaceuticals
tigrispharma.com

Accelerated Pharma

Synnovation Therapeutics
synnovationtx.com

Synspira
Companies similar to Splash Pharmaceuticals include Novita Pharmaceuticals, Camino Pharma, Palm Therapeutics and SphynKx Therapeutics.
Splash Pharmaceuticals was founded in 2001.
Splash Pharmaceuticals' headquarters is located in San Diego, CA, US.
As of May 21, 2018, Splash Pharmaceuticals has raised a total of $23M (USD).
Splash Pharmaceuticals has 1 employee as of Feb 4, 2024.